key: cord-0768273-ue354js9
authors: Zeevat, Florian; Boersma, Cornelis; Postma, Maarten
title: Reply to Anglemyer et al
date: 2021-12-22
journal: J Infect Dis
DOI: 10.1093/infdis/jiab621
sha: 9c72323bf94171ed9ac6f72e71c4f3f343d283d2
doc_id: 768273
cord_uid: ue354js9

nan

To the Editor-We fully agree with Anglemyer et al that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has and will continue to influence the epidemiology and evolution of respiratory infections globally. The exemplary data provided by Anglemyer et al for respiratory syncytial virus may also be reflective of potential developments for influenza, pertussis, and pneumococcal epidemiology, for example concerning the low levels of influenza infections during recent influenza seasons [1, 2] . With potential alleviation of social restrictions as well as SARS-CoV-2 becoming seasonal, seasonal peaks in respiratory infections' burden might be expected, including possible respiratory coinfections. Scarcity of hospital capacity, as exemplified currently by SARS-CoV-2 in various countries, will pose serious challenges and optimized measures are required to prevent and control such outbreaks.

In addition to development of novel and improved respiratory vaccines, testguided antiviral and other antimicrobial therapies, and enhanced use of existing vaccines in vulnerable groups seem crucial to minimize the effects of winter infectious disease burdens. For example, high coverage rates of influenza vaccines and use of best options, such as high-dose formulations for older adults, are warranted [3] . The European Union project VITAL (Vaccines and Infectious Disease in the Ageing Populations, No. 806776) aims to improve vaccines, vaccination programs, and other interventions for vulnerable adult groups, notably to avoid future seasonal peaks in respiratory infections, associated burdens, and potential strains on hospital capacities [4] .

Potential conflicts of interest. FZ, CB and MP have nothing to disclose for this specific manuscript. CB and MP reports grants and personal fees from various medical and pharmaceutical industries, all outside the submitted work. CB holds stocks in Health-Ecore. MP holds stocks in Health-Ecore and Pharmacoeconomics Advice Groningen (PAG Ltd) and is advisor to Asc Academics, all pharmacoeconomic consultancy companies.

Feiten en cijfers

Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: an updated systematic review and metaanalysis

Preventing infectious diseases for healthy ageing: the VITAL public-private partnership project